Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748223 | 0.86 | TDP1 (0.54) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL29579039 | 0.81 | PDGFRB (0.43) | TSHRALDH1A1CYP3A4CYP1A2TDP1 | |
| SCHEMBL259813 | 0.80 | TSHR (0.60) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL629679 | 0.80 | TSHR (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL30829764 | 0.80 | TDP1 (0.53) | TSHRALDH1A1CYP3A4CYP1A2TDP1 | |
| SCHEMBL7787972 | 0.80 | ALDH1A1 (0.59) | TSHRPDE7AALDH1A1CYP3A4TDP1 | |
| SCHEMBL3460888 | 0.80 | TDP1 (0.53) | TSHRALDH1A1CYP3A4CYP1A2TDP1 | |
| SCHEMBL10685212 | 0.80 | CYP1A2 (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL1330407 | 0.80 | TSHR (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL938651 | 0.78 | GPR35 (0.61) | TSHRALDH1A1CYP3A4CYP1A2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| EP-2874621-B1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2874621-B1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9511052-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511052-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511052-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150182503-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150182503-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150182503-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2874621-A2 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010127855-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2008110863-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-6423724-B1 | PREVENTION, THERAPY DISEASE | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-5916900-A | TREATMENT OF NASAL CONGESTION, ASTHMA, COUGH, CARDIOVASCULAR DISORDERS, OCULAR DISORDERS, GASTROINTESTINAL DISORDERS, MIGRAINES, SUSBSTANCE ABUSE | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| US-5716966-A | RESPIRATORY SYSTEM DISORDERS; VISION DEFECTS; GASTROINTESTINAL DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5576437-A | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0734261-A1 | 7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995020386-A1 | 7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | TSHR 770/4885PDE7A 767/4885ALDH1A1 2165/4885 |
| US-20150182503-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, REN | TSHR 297/4885PDE7A 405/4885ALDH1A1 519/4885 |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | TSHR 4393/4885PDE7A 594/4885ALDH1A1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.